- Home
- PMEC vs SNSE Comparison
PMEC vs SNSE Comparison
Compare PMEC & SNSE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PMEC | SNSE |
|---|---|---|
| Founded | 1984 | 2005 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 40.0M | 10.3M |
| IPO Year | 2023 | 2021 |
Fundamental Metrics
Financial Performance| Metric | PMEC | SNSE |
|---|---|---|
| Price | $1.04 | $8.89 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $72.50 |
| AVG Volume (30 Days) | 12.7K | ★ 80.7K |
| Earning Date | 01-01-0001 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $74,349,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 2.52 | N/A |
| 52 Week Low | $0.54 | $5.00 |
| 52 Week High | $2.44 | $18.35 |
Technical Indicators
Market Signals| Indicator | PMEC | SNSE |
|---|---|---|
| Relative Strength Index (RSI) | 43.74 | 52.47 |
| Support Level | $0.99 | $8.50 |
| Resistance Level | $1.09 | $9.60 |
| Average True Range (ATR) | 0.06 | 1.14 |
| MACD | 0.02 | 0.13 |
| Stochastic Oscillator | 39.60 | 31.15 |
Price Performance
Historical ComparisonAbout PMEC Primech Holdings Ltd.
Primech Holdings Ltd is a technology-driven facilities services provider in the public and private sectors operating mainly in Singapore. The services offered by the company include Facilities services, Stewarding services, Cleaning services to offices, Cleaning services to homes, and Cleaning Supplies.
About SNSE Sensei Biotherapeutics Inc.
Sensei Biotherapeutics Inc is an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. Its TMAb (Tumor Microenvironment Activated Biologics) platform developing selective therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. The company have four investigational product candidates in various stages of development: SNS-101 (VISTA), SNS-102 (VSIG4 ), SNS-103 (ENTPDase/CD39), SNS-201 (VISTAxCD28).